VolitionRx (NYSE:VNRX) Given Buy Rating at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock.

Other research analysts have also recently issued reports about the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research note on Wednesday. They set a “sell” rating on the stock.

VolitionRx Stock Performance

VolitionRx stock opened at $0.59 on Wednesday. The company has a market capitalization of $54.58 million, a PE ratio of -1.64 and a beta of 1.09. The company has a 50 day moving average price of $0.61 and a 200-day moving average price of $0.65. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.09.

Hedge Funds Weigh In On VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new position in VolitionRx during the fourth quarter valued at $29,000. Millennium Management LLC purchased a new position in VolitionRx in the fourth quarter valued at $36,000. Northern Trust Corp raised its position in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Geode Capital Management LLC boosted its stake in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. grew its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.